NAI for Sepsis With Persistent Lymphopenia

Official title

Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia

Overview

This is a Phase 2, randomized, open-label study evaluating the safety and efficacy of nogapendekin alfa inbakicept (NAI, ANKTIVA®) in combination with standard of care versus standard of care alone in critically ill adults with sepsis and persistent lymphopenia. The study aims to determine whether NAI can improve 28-day mortality by addressing the immunosuppressive phase of sepsis characterized by persistent lymphopenia (absolute lymphocyte count \<1,000 cells/µL). Participants will be randomized 1:1 to receive either NAI 1.2 mg subcutaneous injection on Days 3 (or earlier if ALC \<700 cells/µL), Day 14, and potentially Day 21 if ALC remains \<1,000 cells/µL, plus standard of care, or standard of care alone. The study will enroll approximately 50 participants (25 per arm) with persistent lymphopenia.

Detailed description

Sepsis is characterized by a biphasic immune response: an initial hyperinflammatory phase followed by a prolonged immunosuppressive phase with persistent lymphopenia. The majority of sepsis deaths (\>70%) occur during the immunosuppressive phase rather than the initial hyperinflammatory phase. This acquired immunosuppression correlates with markedly increased 28-day mortality rates exceeding 40% and significantly elevated risk of secondary infections.

This study evaluates NAI, an IL-15 receptor agonist that promotes proliferation and activation of NK cells and CD8+ T cells, as a potential therapy to restore immune function in critically ill adults with sepsis and persistent lymphopenia (ALC \<1,000 cells/µL on two consecutive measurements within 72 hours of sepsis diagnosis).

Study Arms:

* Experimental Arm: NAI 1.2 mg subcutaneous injection administered on Days 3 (or earlier than Day 3 if ALC is \<700 cells/µL), Day 14, and Day 21 if needed for ALC \<1,000 cells/µL, plus institutional standard of care for sepsis * Control Arm: Institutional standard of care for sepsis alone Standard of care may include antimicrobial therapy, fluid resuscitation, vasopressor support, organ support, and mechanical ventilation as clinically indicated. Treatment will be discontinued if a participant has unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the participant's best interest to continue.

All participants will be followed for 90 days post the first dose of study treatment to capture late adverse events, rehospitalization, or mortality.

Interventions

• Drug Nogapendekin alfa inbakicept (NAI)
  IL-15 receptor agonist complex; 1.2 mg subcutaneous injection administered on Days 3 (or earlier if ALC \<700 cells/µL), Day 14, and Day 21 if needed for ALC \<1,000 cells/µL
• Other Standard of Care (SOC)
  Institutional standard of care for sepsis including antimicrobial therapy, fluid resuscitation, vasopressor support, organ support, and mechanical ventilation as clinically indicated

Primary outcome measures

• 28-day all-cause mortality rate [Time frame: 28 days]

Secondary outcome measures (5)

• Change in absolute lymphocyte count (ALC) [Time frame: Baseline through Day 28]
• ICU re-admission rate [Time frame: Up to Day 90]
• Secondary infections [Time frame: Up to Day 90]
• 90-day all-cause mortality rate [Time frame: 90 days]
• Safety and tolerability [Time frame: Through Day 30 after last dose]

Eligibility criteria

Inclusion criteria

• Age 18 years or older at the time of informed consent
• Admitted to the ICU with a diagnosis of sepsis as defined by Sepsis-3 criteria: life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as a Sequential Organ Failure Assessment (SOFA) score increase of 2 or more points
• Documented persistent lymphopenia defined as ALC <1,000 cells/µL on at least two consecutive measurements within 72 hours of sepsis diagnosis (measurements must be separated by at least 12 hours)
• Prior initiation of appropriate antimicrobial therapy per institutional guidelines
• Ability to obtain written informed consent from the participant or legally authorized representative
• Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males (for up to 7 months after completion of therapy)

Exclusion criteria

• Hematologic malignancies including leukemia, lymphoma, and myelodysplastic syndromes
• Prior CAR-T cell therapy or hematopoietic stem cell transplant (HSCT) within 3 months of screening
• Active cytokine release syndrome (CRS) at screening
• Current or recent (within 7 days) use of colony stimulating factors (G-CSF, GM-CSF)
• Lymphopenia attributable to chemotherapy, radiation therapy, or immunosuppressive medications administered within 30 days prior to screening
• High-dose immunosuppressive therapy (>0.5 mg/kg prednisone equivalent daily), excluding physiologic replacement and stress-dose hydrocortisone for septic shock
• Life expectancy less than 24 hours as assessed by the treating physician
• Active uncontrolled bleeding requiring >2 units of packed red blood cells in the preceding 24 hours
• Known HIV infection with CD4 count <350 cells/µL and detectable viral load
• Known active viral hepatitis (hepatitis B or C with detectable viral load)
• Advanced dementia or other conditions precluding meaningful participation
• Known hypersensitivity to any component of the investigational products
• Participation in another interventional trial with an investigational immunomodulatory agent within 30 days prior to screening
• Pregnant or breastfeeding

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07578558 · ResQ2204-SEPSIS

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗